<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00721396</url>
  </required_header>
  <id_info>
    <org_study_id>V72P12</org_study_id>
    <nct_id>NCT00721396</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules</brief_title>
  <official_title>A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary :1.To demonstrate a sufficient immune response of rMenB+OMV NZ, when given
      concomitantly with routine infant vaccines to healthy infants at 2, 4 and 6 and 2, 3 and 4
      months of age, as measured by percentage of subjects with serum bactericidal activity (SBA)
      titer ≥1:5, at 1 month after the third vaccination Secondary :To demonstrate that
      immunogenicity of routine infant vaccines, when given concomitantly with rMenB+OMV NZ to
      healthy infants at 2, 3 and 4 months of age, was non-inferior to that of routine infant
      vaccines given without rMenB+OMV NZ. 2. To demonstrate that the immunogenicity of rMenB+OMV
      NZ when given concomitantly with routine infant vaccines was non-inferior to that of
      rMenB+OMV NZ given without routine infant vaccines at 2, 4 and 6 months of age. 3. To assess
      prevalence of meningococcal B antibodies over the study period by evaluation of SBA, at
      baseline and at 1 month after third vaccination, in subjects- received routine infant vaccine
      without rMenB+OMV NZ.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Serum Bactericidal Activity ≥1:5 After Receiving Three Doses of rMenB+OMV NZ Vaccine</measure>
    <time_frame>One month after third Men B vaccination</time_frame>
    <description>The percentage of subjects with serum bactericidal activity(hSBA)titer ≥1:5 after receiving three doses of rMenB+OMV NZ vaccine were evaluated to demonstrate sufficient immune response following rMenB+OMV NZ vaccination, when given concomitantly with routine infant vaccines to healthy infants.
The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA).
The immune response was considered sufficient for groups B+R246 and B+R234 if the lower limit of the 2-sided 95% confidence interval was ≥ 70% for all three strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of 3 Doses of rMenB - Concomitantly With Routine Infant Vaccines at 2, 4 and 6 Months of Age - Concomitantly With Routine Vaccines at 2, 3 and 4 Months of Age - Alone at 2, 4 and 6 Months of Age</measure>
    <time_frame>10 months (groups 1 and 2); 8 months (groups 3 and 4)</time_frame>
    <description>Safety and Tolerability of 3 Doses of rMenB was assessed in terms of the number of subjects who reported solicited local and systemic adverse events when administered concomitantly with routine infant vaccines at 2,4,6 months of age (B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-inferiority of Immune Response to rMenB+OMV NZ Vaccination When Administered Concomitantly With Routine Infant Vaccines at 2,4,6 Months of Age</measure>
    <time_frame>One month after 3rd Men B vaccination</time_frame>
    <description>The non-inferiority of immune response to rMenB+OMV NZ vaccination when administered concomitantly with routine infant vaccines at 2,4,6 months of age(B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357)was assessed in terms of percentage of subjects With hSBA≥ 1:5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inferiority of Immune Response to Diphtheria and Tetanus Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine</measure>
    <time_frame>One month after 3rd vaccination</time_frame>
    <description>Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine [group B+R234] to when only routine vaccines were given [Group R234] were assessed in terms of percentage of subjects with antibody concentrations ≥0.1 IU/mL against Diphtheria and Tetanus antigens as measured by enzyme-linked immunosorbent assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers Against Neisseria Meningitidis Serogroup B, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.</measure>
    <time_frame>One month after third Men B vaccination</time_frame>
    <description>The hSBA antibody titers when rMenB+OMV NZ vaccine is administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately are reported in terms of vaccine-group-specific geometric mean titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio of hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.</measure>
    <time_frame>one month after third Men B vaccination</time_frame>
    <description>The geometric mean ratio(GMR) of GMTs at 1 month after 3rd rMenB+OMV NZ vaccination to prevaccination GMTs, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:8 After Receiving Three Doses of rMenB+OMV NZ Vaccine.</measure>
    <time_frame>One month after third Men B vaccination</time_frame>
    <description>The percentage of subjects with hSBA titers ≥1:8, following rMenB+OMV NZ vaccination when given concomitantly with routine infant vaccines to when rMenB+OMV NZ and routine vaccines were given separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 4-fold Rise in hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.</measure>
    <time_frame>One month after third Men B vaccination</time_frame>
    <description>The percentage of subjects with 4-fold rise in hSBA titers at 1 month after 3rd rMenB+OMV NZ vaccination from baseline, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inferiority of Immune Response to Acellular Pertussis Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine.</measure>
    <time_frame>1 month after 3rd vaccination</time_frame>
    <description>Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine [group B+R234] to when only routine vaccines were given [Group R234] were assessed in terms of percentage of subjects achieving seroconversion for pertussis antigens - Filamentous Hemagglutinin (FHA), Pertactin and Pertussis Toxoid (PT) at 1 month after 3rd vaccination versus baseline.
Seroconversion was defined as a 4-fold increase for each pertussis antigen or in those initially seropositive, persistence of the pre-vaccination antibody concentration at least at the same antibody concentration as before vaccination, taking into account the decay of maternal antibodies.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1885</enrollment>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>B+R246</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B246_R357</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B+R234</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R234</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV NZ</intervention_name>
    <arm_group_label>B+R246</arm_group_label>
    <arm_group_label>B246_R357</arm_group_label>
    <arm_group_label>B+R234</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine</intervention_name>
    <arm_group_label>B+R246</arm_group_label>
    <arm_group_label>B246_R357</arm_group_label>
    <arm_group_label>B+R234</arm_group_label>
    <arm_group_label>R234</arm_group_label>
    <other_name>Infanrix Hexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal vaccine</intervention_name>
    <arm_group_label>B+R246</arm_group_label>
    <arm_group_label>B246_R357</arm_group_label>
    <arm_group_label>B+R234</arm_group_label>
    <arm_group_label>R234</arm_group_label>
    <other_name>Prevenar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 2-month old infants (55-89 days, inclusive), who were born after full term
             pregnancy with an estimated gestational age ≥ 37 weeks and a birth weight ≥ 2.5 kg;

          -  For whom a parent/legal guardian has given written informed consent after the nature
             of the study has been explained.

        Exclusion Criteria:

          -  History of any meningococcal B or C vaccine administration;

          -  prior vaccination with routine infant vaccines (Diphtheria, Tetanus, Pertussis, Polio,
             Haemophilus influenzae type b (Hib), and Pneumococcal antigens);

          -  Previous ascertained or suspected disease caused by N. meningitidis;

          -  History of severe allergic reaction after previous vaccinations or hypersensitivity to
             any vaccine component;

          -  Significant acute or chronic infection within the previous 7 days or axillary
             temperature major or equal to38 degrees within the previous day;

          -  Antibiotics within 6 days prior to enrollment;

          -  Any serious chronic or progressive disease;

          -  Known or suspected impairment or alteration of the immune system;

          -  Receipt of blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Days</minimum_age>
    <maximum_age>89 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 59</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Investigational Site Nr. 60</name>
      <address>
        <city>Brussels</city>
        <state>Brussels-Capital Region</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 57</name>
      <address>
        <city>Brussels</city>
        <state>Brussels-Capital Region</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 56</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 55</name>
      <address>
        <city>Antwerp</city>
        <zip>2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 58</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 95</name>
      <address>
        <city>Červený Kostelec</city>
        <state>Hradec Králové</state>
        <zip>549 41</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 96</name>
      <address>
        <city>Jindřichův Hradec</city>
        <state>South Bohemian</state>
        <zip>377 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 93</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 94</name>
      <address>
        <city>Pardubice</city>
        <zip>530 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 68</name>
      <address>
        <city>Bad Saulgau</city>
        <state>Baden-Württemberg</state>
        <zip>88348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 65</name>
      <address>
        <city>Bretten</city>
        <state>Baden-Württemberg</state>
        <zip>75015</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 62</name>
      <address>
        <city>Kehl</city>
        <state>Baden-Württemberg</state>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 64</name>
      <address>
        <city>Oberstenfeld</city>
        <state>Baden-Württemberg</state>
        <zip>71720</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 66</name>
      <address>
        <city>Welzheim</city>
        <state>Baden-Württemberg</state>
        <zip>73642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 69</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bavaria</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 71</name>
      <address>
        <city>Bremerhaven</city>
        <state>Bremen</state>
        <zip>27568</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 73</name>
      <address>
        <city>Baunatal</city>
        <state>Hesse</state>
        <zip>34225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 75</name>
      <address>
        <city>Bramsche</city>
        <state>Lower Saxony</state>
        <zip>49565</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 81</name>
      <address>
        <city>Bochum</city>
        <state>North Rhine-Westphalia</state>
        <zip>44866</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 79</name>
      <address>
        <city>Heiligenhaus</city>
        <state>North Rhine-Westphalia</state>
        <zip>42579</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 80</name>
      <address>
        <city>Kleve Materborn</city>
        <state>North Rhine-Westphalia</state>
        <zip>47533</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 78</name>
      <address>
        <city>Monchengladbach</city>
        <state>North Rhine-Westphalia</state>
        <zip>41236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 82</name>
      <address>
        <city>Munster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 83</name>
      <address>
        <city>Warburg</city>
        <state>North Rhine-Westphalia</state>
        <zip>34414</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 85</name>
      <address>
        <city>Bielefeld</city>
        <state>North-Rhine Westphalia</state>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 61</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 67</name>
      <address>
        <city>Schweigen</city>
        <state>Rhineland-Palatinate</state>
        <zip>76889</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 86</name>
      <address>
        <city>Wanzleben</city>
        <state>Saxony-Anhalt</state>
        <zip>39164</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 88</name>
      <address>
        <city>Itzenhoe</city>
        <state>Schleswig-Holstein</state>
        <zip>25524</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 89</name>
      <address>
        <city>Itzenhoe</city>
        <state>Schleswig-Holstein</state>
        <zip>25524</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 87</name>
      <address>
        <city>Stockelsdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>23617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 90</name>
      <address>
        <city>Erfurt</city>
        <state>Thuringia</state>
        <zip>99086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 70</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 72</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 5</name>
      <address>
        <city>Milano</city>
        <state>Lombardy</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 52</name>
      <address>
        <city>Milano</city>
        <state>Lombardy</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 6</name>
      <address>
        <city>Novara</city>
        <state>Piedmont</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 7</name>
      <address>
        <city>Firenze</city>
        <state>Tuscany</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 9</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 46</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 49</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 11</name>
      <address>
        <city>Almassora</city>
        <state>Castellón</state>
        <zip>12550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 10</name>
      <address>
        <city>Castellon de la Plana</city>
        <state>Castellón</state>
        <zip>12006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 12</name>
      <address>
        <city>Vall D'Uixo</city>
        <state>Castelló</state>
        <zip>12600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 48</name>
      <address>
        <city>Vigo Pontevedra</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 25</name>
      <address>
        <city>Catarroja</city>
        <state>Valencia</state>
        <zip>46470</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 21</name>
      <address>
        <city>La Eliana</city>
        <state>Valencia</state>
        <zip>46183</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 14</name>
      <address>
        <city>Sagunto</city>
        <state>Valencia</state>
        <zip>46500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 17</name>
      <address>
        <city>Valencia</city>
        <zip>46011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 24</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 15</name>
      <address>
        <city>Valencia</city>
        <zip>46021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 18</name>
      <address>
        <city>Valencia</city>
        <zip>46022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 19</name>
      <address>
        <city>Valencia</city>
        <zip>46022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 16</name>
      <address>
        <city>Valencia</city>
        <zip>46024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 23</name>
      <address>
        <city>Valencia</city>
        <zip>46200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 1</name>
      <address>
        <city>Oxford</city>
        <state>South East England</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 3</name>
      <address>
        <city>Bristol</city>
        <state>South West England</state>
        <zip>BS8 1TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 4</name>
      <address>
        <city>Exeter</city>
        <state>South West England</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site Nr. 2</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2008</study_first_submitted>
  <study_first_submitted_qc>July 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2008</study_first_posted>
  <results_first_submitted>February 18, 2015</results_first_submitted>
  <results_first_submitted_qc>March 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 23, 2015</results_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal disease,</keyword>
  <keyword>Neisseria meningitidis serogroup B,</keyword>
  <keyword>Prevention,</keyword>
  <keyword>Vaccination,</keyword>
  <keyword>Infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 4 centers in UK, 5 centers in Italy, 16 centers in Spain, 6 centers in Belgium, 25 centers in Germany and 4 centers in Czech Republic</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>B+R246</title>
          <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations</description>
        </group>
        <group group_id="P2">
          <title>B246_R357</title>
          <description>Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age</description>
        </group>
        <group group_id="P3">
          <title>B+R234</title>
          <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations</description>
        </group>
        <group group_id="P4">
          <title>R234</title>
          <description>Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="627"/>
                <participants group_id="P2" count="628"/>
                <participants group_id="P3" count="318"/>
                <participants group_id="P4" count="312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="597"/>
                <participants group_id="P2" count="592"/>
                <participants group_id="P3" count="308"/>
                <participants group_id="P4" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>B+R246</title>
          <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations</description>
        </group>
        <group group_id="B2">
          <title>B246_R357</title>
          <description>Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age</description>
        </group>
        <group group_id="B3">
          <title>B+R234</title>
          <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations</description>
        </group>
        <group group_id="B4">
          <title>R234</title>
          <description>Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="627"/>
            <count group_id="B2" value="628"/>
            <count group_id="B3" value="318"/>
            <count group_id="B4" value="312"/>
            <count group_id="B5" value="1885"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.7" spread="8.9"/>
                    <measurement group_id="B2" value="68.8" spread="9.4"/>
                    <measurement group_id="B3" value="68.8" spread="9.1"/>
                    <measurement group_id="B4" value="68.1" spread="9.0"/>
                    <measurement group_id="B5" value="68.7" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="292"/>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="159"/>
                    <measurement group_id="B5" value="927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="335"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="154"/>
                    <measurement group_id="B4" value="153"/>
                    <measurement group_id="B5" value="958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Serum Bactericidal Activity ≥1:5 After Receiving Three Doses of rMenB+OMV NZ Vaccine</title>
        <description>The percentage of subjects with serum bactericidal activity(hSBA)titer ≥1:5 after receiving three doses of rMenB+OMV NZ vaccine were evaluated to demonstrate sufficient immune response following rMenB+OMV NZ vaccination, when given concomitantly with routine infant vaccines to healthy infants.
The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA).
The immune response was considered sufficient for groups B+R246 and B+R234 if the lower limit of the 2-sided 95% confidence interval was ≥ 70% for all three strains.</description>
        <time_frame>One month after third Men B vaccination</time_frame>
        <population>The analysis was done on the Modified Intention to Treat (MIIT) population, ie, enrolled subjects who actually received a study vaccination and provided at least one evaluable serum sample after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>B+R246</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O2">
            <title>B246_R357</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age</description>
          </group>
          <group group_id="O3">
            <title>B+R234</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O4">
            <title>R234</title>
            <description>Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Serum Bactericidal Activity ≥1:5 After Receiving Three Doses of rMenB+OMV NZ Vaccine</title>
          <description>The percentage of subjects with serum bactericidal activity(hSBA)titer ≥1:5 after receiving three doses of rMenB+OMV NZ vaccine were evaluated to demonstrate sufficient immune response following rMenB+OMV NZ vaccination, when given concomitantly with routine infant vaccines to healthy infants.
The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA).
The immune response was considered sufficient for groups B+R246 and B+R234 if the lower limit of the 2-sided 95% confidence interval was ≥ 70% for all three strains.</description>
          <population>The analysis was done on the Modified Intention to Treat (MIIT) population, ie, enrolled subjects who actually received a study vaccination and provided at least one evaluable serum sample after baseline.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="587"/>
                <count group_id="O2" value="589"/>
                <count group_id="O3" value="300"/>
                <count group_id="O4" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (44/76-SL strain)N=587,589,300,291</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="6" upper_limit="11"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                    <measurement group_id="O3" value="6" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="O4" value="6" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post vaccination (44/76-SL)N=550,561,283,265</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="4" lower_limit="2" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (5/99 strain)N=580,577,294,289</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                    <measurement group_id="O3" value="5" lower_limit="3" upper_limit="8"/>
                    <measurement group_id="O4" value="6" lower_limit="3" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post vaccination (5/99 strain)N=551,554,285,245</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O4" value="5" lower_limit="3" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline(NZ98/254 strain)N=582,583,298,292</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O4" value="1" lower_limit="0.083" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post vaccination(NZ98/254 strain)N=555,559,284,269</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="75" upper_limit="82"/>
                    <measurement group_id="O2" value="87" lower_limit="84" upper_limit="89"/>
                    <measurement group_id="O3" value="81" lower_limit="76" upper_limit="85"/>
                    <measurement group_id="O4" value="4" lower_limit="2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of 3 Doses of rMenB - Concomitantly With Routine Infant Vaccines at 2, 4 and 6 Months of Age - Concomitantly With Routine Vaccines at 2, 3 and 4 Months of Age - Alone at 2, 4 and 6 Months of Age</title>
        <description>Safety and Tolerability of 3 Doses of rMenB was assessed in terms of the number of subjects who reported solicited local and systemic adverse events when administered concomitantly with routine infant vaccines at 2,4,6 months of age (B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357).</description>
        <time_frame>10 months (groups 1 and 2); 8 months (groups 3 and 4)</time_frame>
        <population>All subjects receiving at least one injection and providing post-baseline safety data (Safety Set).</population>
        <group_list>
          <group group_id="O1">
            <title>B+R246</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations.</description>
          </group>
          <group group_id="O2">
            <title>B246_R357</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+R234</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations.</description>
          </group>
          <group group_id="O4">
            <title>R234</title>
            <description>Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of 3 Doses of rMenB - Concomitantly With Routine Infant Vaccines at 2, 4 and 6 Months of Age - Concomitantly With Routine Vaccines at 2, 3 and 4 Months of Age - Alone at 2, 4 and 6 Months of Age</title>
          <description>Safety and Tolerability of 3 Doses of rMenB was assessed in terms of the number of subjects who reported solicited local and systemic adverse events when administered concomitantly with routine infant vaccines at 2,4,6 months of age (B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357).</description>
          <population>All subjects receiving at least one injection and providing post-baseline safety data (Safety Set).</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="624"/>
                <count group_id="O2" value="627"/>
                <count group_id="O3" value="318"/>
                <count group_id="O4" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness (N=624,626,318,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="529"/>
                    <measurement group_id="O2" value="491"/>
                    <measurement group_id="O3" value="265"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (N=624,626,318,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="506"/>
                    <measurement group_id="O2" value="516"/>
                    <measurement group_id="O3" value="257"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (N=624,626,318,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447"/>
                    <measurement group_id="O2" value="465"/>
                    <measurement group_id="O3" value="230"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=624,626,318,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="324"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits (N=624,626,318,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470"/>
                    <measurement group_id="O2" value="473"/>
                    <measurement group_id="O3" value="249"/>
                    <measurement group_id="O4" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (N=624,626,318,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523"/>
                    <measurement group_id="O2" value="525"/>
                    <measurement group_id="O3" value="282"/>
                    <measurement group_id="O4" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N=624,626,318,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="234"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (N=624,626,318,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284"/>
                    <measurement group_id="O2" value="327"/>
                    <measurement group_id="O3" value="138"/>
                    <measurement group_id="O4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (N=624,626,318,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="543"/>
                    <measurement group_id="O2" value="527"/>
                    <measurement group_id="O3" value="289"/>
                    <measurement group_id="O4" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual Crying (N=624,626,318,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="526"/>
                    <measurement group_id="O2" value="515"/>
                    <measurement group_id="O3" value="268"/>
                    <measurement group_id="O4" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (N=624,626,318,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38.0 C° %) ((N=624,627,318,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="501"/>
                    <measurement group_id="O2" value="447"/>
                    <measurement group_id="O3" value="243"/>
                    <measurement group_id="O4" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-inferiority of Immune Response to rMenB+OMV NZ Vaccination When Administered Concomitantly With Routine Infant Vaccines at 2,4,6 Months of Age</title>
        <description>The non-inferiority of immune response to rMenB+OMV NZ vaccination when administered concomitantly with routine infant vaccines at 2,4,6 months of age(B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357)was assessed in terms of percentage of subjects With hSBA≥ 1:5.</description>
        <time_frame>One month after 3rd Men B vaccination</time_frame>
        <population>Analysis was done on the per-protocol population i.e all subjects in the MITT population who received all the relevant doses of vaccine correctly, provided evaluable serum samples at the relevant time points and had no major protocol violation as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>B+R246</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O2">
            <title>B246_R357</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inferiority of Immune Response to rMenB+OMV NZ Vaccination When Administered Concomitantly With Routine Infant Vaccines at 2,4,6 Months of Age</title>
          <description>The non-inferiority of immune response to rMenB+OMV NZ vaccination when administered concomitantly with routine infant vaccines at 2,4,6 months of age(B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357)was assessed in terms of percentage of subjects With hSBA≥ 1:5.</description>
          <population>Analysis was done on the per-protocol population i.e all subjects in the MITT population who received all the relevant doses of vaccine correctly, provided evaluable serum samples at the relevant time points and had no major protocol violation as defined prior to analysis.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="556"/>
                <count group_id="O2" value="548"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline(44/76-SL strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="11"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 3rd vaccination(44/76-SL)N=525,534</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline(5/99 strain)N=511,537</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 3rd vaccination(5/99strain)N=527,529</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline(NZ98/254 strain)N=554,543</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post 3rd vaccination(NZ98/254 )N=530,534</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="76" upper_limit="83"/>
                    <measurement group_id="O2" value="87" lower_limit="84" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses against 44/76-SL strain when rMenB+OMV NZ vaccine was administered concomitantly with routine infant vaccines as compared to when rMenB+OMV NZ vaccine and routine vaccines were given separately.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Immune response of Group B+R246 was considered non-inferior to response of Group B246_R357, if at one month after the third rMenB+OMV NZ injection the 2-sided 95% lower confidence interval of the difference in the percentage of subjects with hSBA titer ≥1:5 was greater than -10% for each of the 3 strains.</non_inferiority_desc>
            <param_type>Difference % (B+R246 minus B246_R357)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses against 5/99 strain when rMenB+OMV NZ vaccine was administered concomitantly with routine infant vaccines as compared to when rMenB+OMV NZ vaccine and routine vaccines were given separately.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Immune response of Group B+R246 was considered non-inferior to response of Group B246_R357, if at one month after the third rMenB+OMV NZ injection the 2-sided 95% lower confidence limit of the difference in the percentage of subjects with hSBA titer ≥5 was greater than -10% for each of the 3 strains.</non_inferiority_desc>
            <param_type>Difference %(B+R246 minus B246_R357)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses against NZ98/254 strain when rMenB+OMV NZ vaccine was administered concomitantly with routine infant vaccines as compared to when rMenB+OMV NZ vaccine and routine vaccines were given separately.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Immune response of Group B+R246 was considered non-inferior to response of Group B246_R357, if at one month after the third rMenB+OMV NZ injection the 2-sided 95% lower confidence limit of the difference in the percentage of subjects with hSBA titer ≥5 was greater than -10% for each of the 3 strains.</non_inferiority_desc>
            <param_type>Difference % (B+R246 minus B246_R357)</param_type>
            <param_value>-8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12</ci_lower_limit>
            <ci_upper_limit>-4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-inferiority of Immune Response to Diphtheria and Tetanus Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine</title>
        <description>Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine [group B+R234] to when only routine vaccines were given [Group R234] were assessed in terms of percentage of subjects with antibody concentrations ≥0.1 IU/mL against Diphtheria and Tetanus antigens as measured by enzyme-linked immunosorbent assay.</description>
        <time_frame>One month after 3rd vaccination</time_frame>
        <population>All subjects in the Full Analysis Set/MITT population who received all the relevant doses of vaccine correctly, and provided evaluable serum samples at the relevant time points, and had no major protocol violation as defined prior to analysis: Per Protocol (PP) Population.</population>
        <group_list>
          <group group_id="O1">
            <title>B+R234</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O2">
            <title>R234</title>
            <description>Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inferiority of Immune Response to Diphtheria and Tetanus Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine</title>
          <description>Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine [group B+R234] to when only routine vaccines were given [Group R234] were assessed in terms of percentage of subjects with antibody concentrations ≥0.1 IU/mL against Diphtheria and Tetanus antigens as measured by enzyme-linked immunosorbent assay.</description>
          <population>All subjects in the Full Analysis Set/MITT population who received all the relevant doses of vaccine correctly, and provided evaluable serum samples at the relevant time points, and had no major protocol violation as defined prior to analysis: Per Protocol (PP) Population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Diphtheria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="20" upper_limit="30"/>
                    <measurement group_id="O2" value="21" lower_limit="16" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after 3rd vaccination(Diphtheria)N=261,232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Tetanus)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="76" upper_limit="86"/>
                    <measurement group_id="O2" value="86" lower_limit="81" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after 3rd vaccination (Tetanus)N=261,232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses against Diphtheria antigen when routine vaccine was administered concomitantly with rMenB+OMV NZ vaccine to when only routine vaccines were administered.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Immune response of Group B+R234 was considered non-inferior to response of Group R234, if at one month after the third injection the 2-sided 95% lower confidence limit for the difference in the percentage of subjects with antibody response greater than the pre-specified cut off of for diphtheria (≥0.1 IU/mL) was &gt;-10%.</non_inferiority_desc>
            <param_type>Difference %(B+R234 minus R234)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune response to Tetanus antigens when routine vaccines are administered concomitantly with rMen+OMV NZ vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Immune response of Group B+R234 was considered non-inferior to response of Group R234, if at one month after the third injection the 2-sided 95% lower confidence limit for the difference in the percentage of subjects with antibody response greater than the pre-specified cut off of for tetanus toxoid (≥0.1 IU/mL) was &gt;-10%.</non_inferiority_desc>
            <param_type>Difference %(B+R234 minus R234)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers Against Neisseria Meningitidis Serogroup B, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.</title>
        <description>The hSBA antibody titers when rMenB+OMV NZ vaccine is administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately are reported in terms of vaccine-group-specific geometric mean titers.</description>
        <time_frame>One month after third Men B vaccination</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>B+R246</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O2">
            <title>B246_R357</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age</description>
          </group>
          <group group_id="O3">
            <title>B+R234</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O4">
            <title>R234</title>
            <description>Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against Neisseria Meningitidis Serogroup B, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.</title>
          <description>The hSBA antibody titers when rMenB+OMV NZ vaccine is administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately are reported in terms of vaccine-group-specific geometric mean titers.</description>
          <population>PP Population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="556"/>
                <count group_id="O2" value="548"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (44/76-SL strain) N=556,548,285,277</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="1.4" upper_limit="1.59"/>
                    <measurement group_id="O2" value="1.36" lower_limit="1.28" upper_limit="1.46"/>
                    <measurement group_id="O3" value="1.34" lower_limit="1.23" upper_limit="1.46"/>
                    <measurement group_id="O4" value="1.28" lower_limit="1.19" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post vaccination (44/76-SL) N=525,534,273,253</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="80" upper_limit="92"/>
                    <measurement group_id="O2" value="113" lower_limit="105" upper_limit="121"/>
                    <measurement group_id="O3" value="82" lower_limit="75" upper_limit="91"/>
                    <measurement group_id="O4" value="1.16" lower_limit="1.09" upper_limit="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (5/99 strain) N=551,537,280,275</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.21" upper_limit="1.39"/>
                    <measurement group_id="O2" value="1.28" lower_limit="1.2" upper_limit="1.37"/>
                    <measurement group_id="O3" value="1.19" lower_limit="1.09" upper_limit="1.3"/>
                    <measurement group_id="O4" value="1.24" lower_limit="1.15" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post vaccination (5/99 strain)N=527,529,275,236</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="537" lower_limit="494" upper_limit="584"/>
                    <measurement group_id="O2" value="699" lower_limit="643" upper_limit="759"/>
                    <measurement group_id="O3" value="325" lower_limit="292" upper_limit="362"/>
                    <measurement group_id="O4" value="1.25" lower_limit="1.08" upper_limit="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (NZ98/254 strain)N=554,543,283,278</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="1.08" upper_limit="1.18"/>
                    <measurement group_id="O2" value="1.08" lower_limit="1.04" upper_limit="1.13"/>
                    <measurement group_id="O3" value="1.06" lower_limit="1" upper_limit="1.12"/>
                    <measurement group_id="O4" value="1.07" lower_limit="1.03" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post vaccination (NZ98/254 strain)N=30,534,274,257</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="11" upper_limit="14"/>
                    <measurement group_id="O2" value="18" lower_limit="16" upper_limit="20"/>
                    <measurement group_id="O3" value="11" lower_limit="9.14" upper_limit="12"/>
                    <measurement group_id="O4" value="1.11" lower_limit="1.04" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio of hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.</title>
        <description>The geometric mean ratio(GMR) of GMTs at 1 month after 3rd rMenB+OMV NZ vaccination to prevaccination GMTs, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.</description>
        <time_frame>one month after third Men B vaccination</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>B+R246</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O2">
            <title>B246_R357</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age</description>
          </group>
          <group group_id="O3">
            <title>B+R234</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O4">
            <title>R234</title>
            <description>Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio of hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.</title>
          <description>The geometric mean ratio(GMR) of GMTs at 1 month after 3rd rMenB+OMV NZ vaccination to prevaccination GMTs, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.</description>
          <population>PP Population</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="507"/>
                <count group_id="O3" value="262"/>
                <count group_id="O4" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>44/76-SL strain (N=501,507,262,236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="52" upper_limit="64"/>
                    <measurement group_id="O2" value="83" lower_limit="74" upper_limit="92"/>
                    <measurement group_id="O3" value="61" lower_limit="53" upper_limit="70"/>
                    <measurement group_id="O4" value="0.91" lower_limit="0.83" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (N=497,494,257,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430" lower_limit="379" upper_limit="487"/>
                    <measurement group_id="O2" value="553" lower_limit="489" upper_limit="625"/>
                    <measurement group_id="O3" value="271" lower_limit="231" upper_limit="318"/>
                    <measurement group_id="O4" value="1.03" lower_limit="0.86" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 strain (N=504,503,258,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9.28" upper_limit="12"/>
                    <measurement group_id="O2" value="16" lower_limit="14" upper_limit="19"/>
                    <measurement group_id="O3" value="10" lower_limit="8.52" upper_limit="12"/>
                    <measurement group_id="O4" value="1.05" lower_limit="0.97" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:8 After Receiving Three Doses of rMenB+OMV NZ Vaccine.</title>
        <description>The percentage of subjects with hSBA titers ≥1:8, following rMenB+OMV NZ vaccination when given concomitantly with routine infant vaccines to when rMenB+OMV NZ and routine vaccines were given separately.</description>
        <time_frame>One month after third Men B vaccination</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>B+R246</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O2">
            <title>B246_R357</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age</description>
          </group>
          <group group_id="O3">
            <title>B+R234</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O4">
            <title>R234</title>
            <description>Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:8 After Receiving Three Doses of rMenB+OMV NZ Vaccine.</title>
          <description>The percentage of subjects with hSBA titers ≥1:8, following rMenB+OMV NZ vaccination when given concomitantly with routine infant vaccines to when rMenB+OMV NZ and routine vaccines were given separately.</description>
          <population>PP Population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="556"/>
                <count group_id="O2" value="548"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (44/76-SL strain)N=556,548,285,277</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O3" value="4" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="O4" value="2" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post vaccination (44/76-SL)N=525,534,273,253</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (5/99 strain)N=551,537,280,275</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O3" value="2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O4" value="4" lower_limit="2" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post vaccination (5/99 strain)N=527,529,275,236</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O4" value="3" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline(NZ98/254 strain)N=554,543,283,278</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="1" lower_limit="0.086" upper_limit="3"/>
                    <measurement group_id="O4" value="0.1" lower_limit="0.0091" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post vaccination(NZ98/254 strain)N=530,534,274,257</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="63" upper_limit="71"/>
                    <measurement group_id="O2" value="79" lower_limit="75" upper_limit="82"/>
                    <measurement group_id="O3" value="69" lower_limit="63" upper_limit="74"/>
                    <measurement group_id="O4" value="2" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 4-fold Rise in hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.</title>
        <description>The percentage of subjects with 4-fold rise in hSBA titers at 1 month after 3rd rMenB+OMV NZ vaccination from baseline, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.</description>
        <time_frame>One month after third Men B vaccination</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>B+R246</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O2">
            <title>B246_R357</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age</description>
          </group>
          <group group_id="O3">
            <title>B+R234</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O4">
            <title>R234</title>
            <description>Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 4-fold Rise in hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.</title>
          <description>The percentage of subjects with 4-fold rise in hSBA titers at 1 month after 3rd rMenB+OMV NZ vaccination from baseline, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.</description>
          <population>PP Population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="507"/>
                <count group_id="O3" value="262"/>
                <count group_id="O4" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>44/76-SL strain (N=501,507,262,236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="99" lower_limit="97" upper_limit="99"/>
                    <measurement group_id="O3" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (N=497,494,257,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O4" value="3" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 strain (N=504,503,258,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="62" upper_limit="70"/>
                    <measurement group_id="O2" value="78" lower_limit="74" upper_limit="81"/>
                    <measurement group_id="O3" value="69" lower_limit="63" upper_limit="75"/>
                    <measurement group_id="O4" value="3" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-inferiority of Immune Response to Acellular Pertussis Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine.</title>
        <description>Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine [group B+R234] to when only routine vaccines were given [Group R234] were assessed in terms of percentage of subjects achieving seroconversion for pertussis antigens - Filamentous Hemagglutinin (FHA), Pertactin and Pertussis Toxoid (PT) at 1 month after 3rd vaccination versus baseline.
Seroconversion was defined as a 4-fold increase for each pertussis antigen or in those initially seropositive, persistence of the pre-vaccination antibody concentration at least at the same antibody concentration as before vaccination, taking into account the decay of maternal antibodies.</description>
        <time_frame>1 month after 3rd vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B+R234</title>
            <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations</description>
          </group>
          <group group_id="O2">
            <title>R234</title>
            <description>Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inferiority of Immune Response to Acellular Pertussis Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine.</title>
          <description>Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine [group B+R234] to when only routine vaccines were given [Group R234] were assessed in terms of percentage of subjects achieving seroconversion for pertussis antigens - Filamentous Hemagglutinin (FHA), Pertactin and Pertussis Toxoid (PT) at 1 month after 3rd vaccination versus baseline.
Seroconversion was defined as a 4-fold increase for each pertussis antigen or in those initially seropositive, persistence of the pre-vaccination antibody concentration at least at the same antibody concentration as before vaccination, taking into account the decay of maternal antibodies.</description>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="90" upper_limit="97"/>
                    <measurement group_id="O2" value="95" lower_limit="91" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="88" upper_limit="95"/>
                    <measurement group_id="O2" value="95" lower_limit="91" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="98" lower_limit="95" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses against Pertussis antigen FHA when routine vaccine was administered concomitantly with rMenB+OMV NZ vaccine to when only routine vaccines were administered.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Group B+R234 was to be considered non-inferior to Group R234 if the 2-sided 95% lower confidence limit of this difference at 30 days after the last injection was greater than -10% for each of the antigens of the routine vaccinations.</non_inferiority_desc>
            <param_type>Difference %(B+R234 minus R234)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses against Pertussis antigen pertactin antigen when routine vaccine was administered concomitantly with rMenB+OMV NZ vaccine to when only routine vaccines were administered.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Group B+R234 was to be considered non-inferior to Group R234 if the 2-sided 95% lower confidence limit of this difference at 30 days after the last injection was greater than -10% for each of the antigens of the routine vaccinations.</non_inferiority_desc>
            <param_type>Difference %(B+R234 minus R234)</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses against Pertussis antigen PT when routine vaccine was administered concomitantly with rMenB+OMV NZ vaccine to when only routine vaccines were administered.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Group B+R234 was to be considered non-inferior to Group R234 if the 2-sided 95% lower confidence limit of this difference at 30 days after the last injection was greater than -10% for each of the antigens of the routine vaccinations.</non_inferiority_desc>
            <param_type>Difference %(B+R234 minus R234)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited and unsolicited AEs were collected for 7 days after each vaccination; SAEs, Medically attended AEs and AEs leading to premature withdrawal were collected throughout the study period.</time_frame>
      <desc>Of the 1885 enrolled subjects, 1882 received at least one vaccination and provided post-baseline safety data; these subjects were included in the safety analysis (B+R246 [625], B246_R357 [627], B+R234 [318], R234 [312]. Three subjects did not receive any vaccination and were excluded from the safety analysis (B+R246 [2], B246_R357 [1]).</desc>
      <group_list>
        <group group_id="E1">
          <title>B+R246</title>
          <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations</description>
        </group>
        <group group_id="E2">
          <title>B246_R357</title>
          <description>Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age</description>
        </group>
        <group group_id="E3">
          <title>B+R234</title>
          <description>Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations</description>
        </group>
        <group group_id="E4">
          <title>R234</title>
          <description>Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadentitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital musculoskeletal anomaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Craniosynostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Talipes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Urachal abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal dystrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Developmental delay</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gatroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gatroenteritis adenovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gatroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Lymph gland infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Glioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hypotonic-hyporesponsive episode</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aponetic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="620" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="623" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="316" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="305" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="302" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="338" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="145" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="123" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="208" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="245" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="489" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="519" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="254" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="204" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="514" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="462" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="246" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="176" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="535" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="553" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="271" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="229" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="328" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="383" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="170" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="115" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="526" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="516" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="268" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="187" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="544" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="536" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="279" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="182" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="523" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="525" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="282" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="224" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="543" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="527" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="289" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="220" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Eating disorder</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="470" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="473" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="249" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="159" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="625"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="627"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="318"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

